Choose your region:

How do equipment changes affect pharmaceutical formulation scale-up?

Equipment changes during pharmaceutical formulation scale-up directly affect critical process parameters such as mixing dynamics, heat transfer, and shear forces, often in ways that are not linearly predictable from lab-scale results. Even well-characterized formulations can behave differently when transferred to larger vessels or different equipment geometries. The sections below unpack the most important questions researchers and process scientists face when scaling up pharmaceutical formulations in the Benelux and beyond.

What are the most critical equipment parameters that change during scale-up?

The most critical equipment parameters that change during pharmaceutical formulation scale-up are impeller geometry, vessel aspect ratio, power-to-volume ratio, surface-area-to-volume ratio, and pump or transfer line specifications. These parameters govern how energy is distributed through a batch and how uniformly a formulation behaves, and they rarely scale linearly from bench to pilot to production.

At laboratory scale, a researcher works with small volumes where gravitational effects are minimal and manual adjustments are easy. As volume increases, the same nominal agitation speed produces very different shear profiles, flow patterns, and residence time distributions. Equipment that performs identically on paper can produce dramatically different outcomes in practice because the underlying fluid mechanics change with scale.

Key parameters to evaluate when planning a scale-up include:

  • Power number and tip speed of impellers, which determine shear intensity
  • Reynolds number, which governs whether flow is laminar or turbulent
  • Nozzle and sparger geometry in systems where gas introduction matters
  • Wall thickness and material of reaction vessels, affecting heat conduction
  • Pump type and flow rate for transfer steps, especially with shear-sensitive formulations

Understanding which parameters are most sensitive for a given formulation type is the starting point for any robust scale-up strategy.

How does mixing equipment affect product homogeneity at larger scales?

Mixing equipment affects product homogeneity at larger scales because the ratio of mixing time to reaction or dissolution time changes as vessel volume increases. In larger vessels, dead zones, stratification, and insufficient blend uniformity become more likely, particularly for viscous formulations or systems where particle suspension is required.

At lab scale, even a poorly designed mixing setup can produce acceptable homogeneity simply because diffusion distances are short and mixing times are fast relative to the process. At production scale, this forgiving behavior disappears. The impeller must be carefully matched to the vessel geometry, and baffling, off-center positioning, or multi-impeller configurations may be necessary to eliminate stagnant regions.

For formulations containing active pharmaceutical ingredients (APIs) that must be uniformly distributed throughout a matrix, inadequate mixing at scale is one of the most common root causes of batch failure. Blend uniformity testing and in-process sampling at multiple vessel locations are standard approaches for detecting mixing-related heterogeneity during scale-up campaigns.

Why do heat transfer and temperature control become harder to maintain at scale?

Heat transfer and temperature control become harder to maintain at scale because the surface-area-to-volume ratio decreases as vessel size increases. A larger vessel has proportionally less jacket surface area relative to the volume of material it contains, which means the same temperature setpoint requires more efficient heat exchange or a longer equilibration time.

This geometric reality has direct consequences for exothermic reactions and temperature-sensitive formulations. At lab scale, a jacketed vessel can respond quickly to a temperature deviation because the thermal mass is small. At pilot or production scale, the same deviation may take significantly longer to correct, and localized hotspots near heating or cooling surfaces can emerge.

Several factors compound this challenge:

  • Higher-viscosity formulations have lower thermal conductivity, slowing heat transfer further
  • Larger vessels may require internal coils in addition to external jackets to achieve target heat removal rates
  • The thermal inertia of the vessel wall itself becomes a significant variable at production scale
  • Thermostat capacity must be matched to the worst-case heat load, not just average operating conditions

Thermostat systems and precision temperature control units play a central role in managing these challenges. Selecting equipment with sufficient heating and cooling capacity (and verifying that capacity with calorimetric studies during scale-up) is essential for maintaining formulation quality.

What equipment changes trigger a revalidation requirement under GMP?

Under GMP principles, equipment changes that affect critical quality attributes (CQAs) or critical process parameters (CPPs) of a pharmaceutical product trigger a revalidation requirement. This includes changes to reactor type, vessel size, agitation system, heat transfer equipment, and any instrumentation used for in-process control or data integrity purposes.

The regulatory logic is straightforward: validation demonstrates that a process consistently produces a product meeting its predetermined specifications. When the equipment used in that process changes materially, the original validation evidence no longer applies. A change control procedure must assess whether the change is minor, major, or critical, and the classification determines the extent of revalidation required.

Common equipment changes that typically require revalidation include switching from one vessel geometry to another, replacing an agitator with a different impeller type, upgrading a thermostat or heat exchanger, and changing instrumentation that feeds into electronic batch records under 21 CFR Part 11 or equivalent frameworks. Even seemingly minor upgrades, such as replacing a sensor model, can require qualification activities such as IQ (Installation Qualification) and OQ (Operational Qualification) to maintain a compliant state.

Documenting the rationale for any equipment change and assessing its impact on validated parameters before implementation is the foundation of a defensible change control program in pharmaceutical manufacturing.

How does switching from batch to flow synthesis affect formulation scale-up?

Switching from batch to flow synthesis during pharmaceutical formulation scale-up fundamentally changes how mixing, heat transfer, and reaction control are achieved. In flow systems, reactions occur in a continuous stream through narrow channels or tubular reactors rather than in a stirred vessel, which means residence time, mixing efficiency, and temperature uniformity are governed by flow rate and reactor geometry rather than impeller speed and vessel volume.

This transition can offer significant advantages for scale-up. Because the reactor dimensions remain small even at high throughput, the surface-area-to-volume ratio stays favorable, making heat transfer far more controllable than in large batch vessels. Exothermic reactions that are difficult to manage safely at batch scale can often be handled more predictably in flow.

However, the switch also introduces new challenges. Formulations must be pumpable and stable under the shear conditions of continuous flow. Solid-liquid systems require careful consideration of particle size and suspension stability to avoid blockages. Residence time distribution must be characterized to ensure consistent product quality. And from a regulatory standpoint, moving from a validated batch process to a flow process is a major change that requires a full assessment of the impact on CQAs and a corresponding validation program.

For research organizations in the Benelux exploring continuous manufacturing or flow chemistry as part of their development strategy, understanding these trade-offs early in the process development phase reduces the risk of costly late-stage redesign.

What strategies reduce scale-up failure risk when changing equipment?

The most effective strategies for reducing scale-up failure risk when changing equipment are early risk assessment, dimensionless number-based scaling, incremental scale transitions, and robust in-process monitoring. Applying these strategies systematically, rather than relying on empirical trial and error, significantly increases the probability of a successful technology transfer.

A structured approach to scale-up risk reduction typically follows these steps:

  1. Identify critical process parameters early. Use small-scale experiments to map which parameters most strongly influence CQAs before any equipment change is made.
  2. Apply dimensionless scaling principles. Use Reynolds number, Froude number, and power-to-volume ratios to predict how process behavior will change with equipment geometry rather than simply scaling by volume.
  3. Use intermediate scale steps. Moving directly from lab to full production scale skips important learning opportunities. Pilot-scale runs reveal equipment-specific behaviors that cannot be predicted from first principles alone.
  4. Implement in-process analytical tools. Real-time monitoring of temperature, viscosity, particle size, or spectroscopic endpoints provides early warning of process deviations during scale-up campaigns.
  5. Document and assess every equipment change formally. A robust change control system ensures that no modification proceeds without a documented impact assessment and appropriate qualification activities.

Collaboration between formulation scientists, process engineers, and equipment specialists is equally important. Equipment selection decisions made without input from those who understand the formulation’s sensitivity to shear, temperature, or mixing time are a leading source of avoidable scale-up failures.

How ChemSPX supports pharmaceutical formulation scale-up

Navigating equipment changes during pharmaceutical formulation scale-up requires both deep process knowledge and access to the right instrumentation. ChemSPX supports research and development teams across the Benelux with expert guidance and high-end laboratory instruments tailored to the demands of chemical synthesis, purification, and process scale-up.

  • Advisory support from Sales Engineers and Product Specialists with application-level expertise in batch and flow synthesis
  • Instrumentation for synthesis, thermostats, and preparative chromatography suited to research and pilot-scale workflows
  • IQ/OQ installation and qualification services in line with GMP and GLP requirements
  • Ongoing service and calibration support to keep instruments compliant and performing reliably throughout the product lifecycle

Whether you are evaluating a transition from batch to flow, selecting thermostat equipment for a new scale, or planning a revalidation after an equipment change, the ChemSPX team is available to advise. Contact ChemSPX to discuss your scale-up challenges with a specialist.

Foire aux questions

How do I know which dimensionless numbers are most relevant for my specific formulation type?

The most relevant dimensionless numbers depend on the dominant physical phenomena in your process. For mixing-intensive operations, the Reynolds number (flow regime) and Power number (energy input) are typically primary; for systems where surface tension or gas-liquid interfaces matter, the Weber number becomes important; and for heat-transfer-critical processes, the Nusselt and Prandtl numbers take priority. A practical starting point is to identify your formulation’s most sensitive CQA — whether that is blend uniformity, particle size, or temperature-dependent degradation — and work backward to the dimensionless group that governs it. Consulting with a process engineer or equipment specialist early in development can help you avoid over-engineering the scaling analysis.

What are the most common mistakes teams make when scaling up for the first time?

The most common mistake is assuming that a process that works well at lab scale will behave predictably at pilot or production scale simply by multiplying volumes. Teams often overlook how dramatically fluid dynamics, heat transfer, and mixing time ratios shift with increasing vessel size. Another frequent error is skipping intermediate scale steps to save time, which removes the opportunity to detect equipment-specific behaviors before they cause a full-scale batch failure. Finally, making equipment selection decisions in isolation — without input from both formulation scientists and process engineers — frequently leads to mismatches between the formulation’s sensitivity profile and the chosen equipment’s operating envelope.

How early in the development process should equipment scale-up planning begin?

Equipment scale-up planning should ideally begin during the late research or early pre-formulation phase, well before the first pilot campaign. At this stage, even a high-level assessment of which process parameters are likely to be scale-sensitive can inform equipment selection and help avoid design decisions that create problems later. Waiting until a formulation is fully characterized before considering scale-up constraints is a common source of costly late-stage redesign. Early engagement with equipment specialists allows development teams to design small-scale experiments that generate scale-relevant data from the outset.

Can in-process analytical tools be used during scale-up even if they were not part of the original lab-scale method?

Yes, and in many cases introducing in-process analytical tools specifically for the scale-up campaign is strongly advisable, even if they were not used at lab scale. Techniques such as inline Raman spectroscopy, focused beam reflectance measurement (FBRM) for particle sizing, or real-time viscosity monitoring can detect process deviations far earlier than offline sampling alone. However, any new analytical tool introduced into a GMP-relevant process must be qualified and its data integrity controls assessed in line with applicable regulatory requirements, such as 21 CFR Part 11 or EU Annex 11. The investment in qualification is generally offset by the risk reduction these tools provide during scale-up campaigns.

What should be included in a change control assessment when switching to a larger vessel?

A thorough change control assessment for a vessel size change should document the original validated parameters, identify all CPPs and CQAs that could be affected by the new geometry, and provide a scientific rationale for why the change is classified as minor, major, or critical. Specifically, it should address differences in impeller geometry, power-to-volume ratio, surface-area-to-volume ratio, and any instrumentation changes that accompany the new vessel. The assessment should also outline the qualification activities required — typically IQ and OQ at minimum, and potentially a process performance qualification (PPQ) run — and define acceptance criteria before any production batches are manufactured on the new equipment.

Are there formulation types that are particularly high-risk during equipment-driven scale-up?

Yes, several formulation types carry elevated scale-up risk when equipment changes are involved. Shear-sensitive formulations — including emulsions, liposomal systems, and protein-based drug products — are particularly vulnerable because even modest changes in impeller tip speed or pump type can alter particle size distribution or cause aggregation. Highly viscous systems are also high-risk because their mixing and heat transfer behavior is strongly non-linear with scale. Formulations containing polymorphic APIs that can undergo form conversion under different temperature or shear conditions require especially careful thermal and mechanical characterization at each new scale before process parameters are locked.

What is the difference between IQ, OQ, and PQ, and which is required after an equipment change?

Installation Qualification (IQ) confirms that equipment has been installed correctly according to manufacturer specifications and site requirements. Operational Qualification (OQ) verifies that the equipment operates as intended across its defined operating range. Process Performance Qualification (PQ) demonstrates that the process consistently produces product meeting specifications when run on that equipment under normal operating conditions. After an equipment change, the minimum typically required is IQ and OQ to re-establish the equipment’s qualified state; PQ is generally required when the change affects a step directly linked to a CQA, or when moving to a significantly different scale or equipment type. The specific scope should always be determined through a formal impact assessment within your change control system.

Articles connexes

Ce contenu a été généré à l'aide de l'IA et peut contenir des erreurs.

Contact our Xperts

Prefer to give us a call?

Belgium & Luxembourg
+32 (02)2 334 22 70

Please select your country

By selecting your country, we can show you the products that are available for you and your organisation.